Literature DB >> 3519141

Drug interactions with oral contraceptives.

P F D'Arcy.   

Abstract

In the very rare cases where a pregnancy occurs during oral contraceptive use, the blame is usually laid against the patient for having forgotten to take the pill. Evidence has started to accumulate to suggest that neither the patient nor the pill is at fault in some contraceptive failures. It may be because the patient is taking other medicines and these may be preventing the pill from suppressing ovulation. Most drug interactions reducing or negating contraceptive activity are due to concomitant use of drugs having microsomal enzyme-inducing activity (e.g., some antibiotics, especially rifampicin, and anticonvulsants, including phenobarbital, phenytoin, and primidone. Other antibiotics (e.g., tetracycline) may also interact by interruption of the enterohepatic circulation of contraceptive steroids. Less well appreciated, oral contraceptive steroids may themselves modify the metabolism and pharmacological activity of various other drugs (e.g., anticoagulants, benzodiazepines, beta-blockers, caffeine, corticosteroids, and tricyclic antidepressants); in this respect the oral contraceptives are acting as enzyme inhibitors. Contraceptive steroids may also interact with drugs that cause enzyme inhibition and this delays the metabolism of the hormonal agents. Interactions of this type would be expected to potentiate the action of the contraceptive steroids. It is suggested that the effects of such interaction might be presented in terms of increased incidence of side effects, including water retention, diabetogenic effects, hypertension, and an increased risk of thromboembolic disorders. The spectrum of interactions with oral contraceptives is presented in three tables.

Entities:  

Keywords:  Adrenal Cortex Hormones; Antibiotics; Biology; Bleeding; Contraception; Contraceptive Agents; Contraceptive Agents, Female; Contraceptive Methods; Diseases; Drugs--pharmacodynamics; Endocrine Effects; Endocrine System; Family Planning; Hepatic Effects; Hormones; Menstruation; Menstruation Disorders; Metrorrhagia; Oral Contraceptives; Physiology; Reproduction; Signs And Symptoms; Treatment; Urogenital System

Mesh:

Substances:

Year:  1986        PMID: 3519141     DOI: 10.1177/106002808602000504

Source DB:  PubMed          Journal:  Drug Intell Clin Pharm        ISSN: 0012-6578


  9 in total

Review 1.  Pharmacokinetic drug interactions between oral contraceptives and second-generation anticonvulsants.

Authors:  K Wilbur; M H Ensom
Journal:  Clin Pharmacokinet       Date:  2000-04       Impact factor: 6.447

2.  Effect of oral contraceptive steroids on the pharmacokinetics of phenprocoumon.

Authors:  H Mönig; C Baese; H T Heidemann; E E Ohnhaus; H M Schulte
Journal:  Br J Clin Pharmacol       Date:  1990-07       Impact factor: 4.335

Review 3.  How important are gender differences in pharmacokinetics?

Authors:  Bernd Meibohm; Ingrid Beierle; Hartmut Derendorf
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 4.  Interactions between antiepileptic drugs and hormonal contraception.

Authors:  Pamela Crawford
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

Review 5.  Clinical pharmacokinetics of contraceptive steroids. An update.

Authors:  G M Shenfield; J M Griffin
Journal:  Clin Pharmacokinet       Date:  1991-01       Impact factor: 6.447

Review 6.  Contraception and mental health: a commentary on the evidence and principles for practice.

Authors:  Kelli Stidham Hall; Julia R Steinberg; Carrie A Cwiak; Rebecca H Allen; Sheila M Marcus
Journal:  Am J Obstet Gynecol       Date:  2014-12-12       Impact factor: 8.661

Review 7.  Long-cycle treatment with oral contraceptives.

Authors:  Inka Wiegratz; Herbert Kuhl
Journal:  Drugs       Date:  2004       Impact factor: 9.546

8.  No interaction between ciprofloxacin and an oral contraceptive.

Authors:  P C Scholten; R M Droppert; M G Zwinkels; H L Moesker; J J Nauta; I M Hoepelman
Journal:  Antimicrob Agents Chemother       Date:  1998-12       Impact factor: 5.191

9.  A Multi-Center, Open-Label, Pharmacokinetic Drug Interaction Study of Erenumab and a Combined Oral Contraceptive in Healthy Females.

Authors:  Yang Xu; Kristin Gabriel; Yi Wang; Yanchen Zhou; Osaro Eisele; Apinya Vutikullird; Daniel D Mikol; Edward Lee
Journal:  CNS Drugs       Date:  2019-05       Impact factor: 5.749

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.